Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.

A paid market commentary issued by USA News Group highlights AbCellera as an established example of a platform combining AI discovery with wet-lab validation. The article notes AbCellera's shares reportedly rose approximately 64% in 2026 following encouraging Phase 2 data from an internal program, alongside a substantial cash position.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.